Share on StockTwits

Vical (NASDAQ:VICL) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued on Tuesday. The firm currently has a $1.30 price target on the stock. Zacks‘s price objective indicates a potential upside of 11.11% from the stock’s current price.

Vical (NASDAQ:VICL) traded up 0.43% during mid-day trading on Tuesday, hitting $1.175. 400,984 shares of the company’s stock traded hands. Vical has a 52-week low of $1.01 and a 52-week high of $4.51. The stock has a 50-day moving average of $1.19 and a 200-day moving average of $1.2. The company’s market cap is $102.0 million.

Vical (NASDAQ:VICL) last announced its earnings results on Thursday, May 1st. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.01. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.60 million. During the same quarter last year, the company posted ($0.11) earnings per share. Vical’s revenue was up 50.0% compared to the same quarter last year. On average, analysts predict that Vical will post $-0.17 earnings per share for the current fiscal year.

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (NASDAQ:VICL) delivery technologies for the prevention and treatment of serious or life-threatening diseases.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.